Celebrex 200 Mg Capsule (Celecoxib) – Targeted COX-2 Anti-Inflammatory Therapy

Celebrex 200 Mg Capsule (Celecoxib) is a selective cyclooxygenase-2 (COX-2) nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of acute pain, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and primary dysmenorrhea in adults. By selectively inhibiting COX-2 without significantly interfering with constitutive COX-1 activity at therapeutic doses, it reduces inflammatory prostaglandin synthesis while maintaining a comparatively lower risk of serious upper gastrointestinal adverse events.

What Is Celebrex 200 Mg?

Celebrex 200 Mg contains celecoxib, a diaryl-substituted pyrazole derivative. It represents the first widely approved selective COX-2 inhibitor designed to provide anti-inflammatory and analgesic efficacy comparable to non-selective NSAIDs such as naproxen, ibuprofen, or diclofenac.

The 200 Mg strength is one of the standard therapeutic oral doses used for chronic joint inflammation, acute musculoskeletal flare-ups, and systemic inflammatory arthritis. It can be administered as a single daily dose or divided into two daily administrations depending on the specific clinical indication.

As with all prescription NSAIDs, Celebrex should be prescribed at the lowest effective dose for the shortest possible duration consistent with individual patient treatment objectives.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

How Does Celebrex 200 Mg Work?

Prostaglandins are key biological mediators that promote pain signaling, joint swelling, tissue inflammation, and fever. Their production requires the cyclooxygenase pathway:

• COX-1 Enzyme (Constitutive): Present in most tissues; responsible for synthesizing prostaglandins that protect the gastrointestinal mucosa, regulate renal blood flow, and support platelet aggregation through thromboxane A2.
• COX-2 Enzyme (Inducible): Primarily upregulated at sites of inflammation in response to pro-inflammatory cytokines, tissue injury, and mechanical joint stress.

Celecoxib selectively inhibits the COX-2 isozyme, blocking inflammatory prostaglandin E2 (PGE2) synthesis while largely sparing COX-1 activity at therapeutic plasma concentrations. This provides pain relief and resolves joint swelling while reducing the frequency of gastric mucosal ulcerations seen with traditional non-selective NSAIDs.

What Is Celebrex 200 Mg Used For?

Celebrex 200 Mg is approved for the clinical management of multiple acute and chronic inflammatory conditions:

• Osteoarthritis (OA): Relief of chronic joint stiffness, swelling, and degenerative arthritic pain.
• Rheumatoid Arthritis (RA): Long-term reduction of systemic joint pain, tenderness, and synovial effusion in adult patients.
• Ankylosing Spondylitis (AS): Management of spinal stiffness, axial skeletal inflammation, and back pain.
• Acute Musculoskeletal & Post-Surgical Pain: Rapid-onset management of acute surgical, dental, or soft-tissue injury pain.
• Primary Dysmenorrhea: Relief of severe menstrual cramps and associated lower pelvic pain.

Celebrex is not intended for the treatment of viral headache or mild, transient aches that resolve with over-the-counter analgesics.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Related COX-2 Selective Formulations

For alternative selective COX-2 inhibitor strengths and once-daily second-generation options, explore our related clinical product profiles:

Celebrex 200 Mg Dosage and Administration

Dosing schedules should be tailored to the specific condition, using the lowest effective dose:

• Osteoarthritis: 200 Mg once daily, or 100 Mg taken twice daily.
• Rheumatoid Arthritis: 100 Mg to 200 Mg twice daily.
• Ankylosing Spondylitis: 200 Mg once daily, or 100 Mg twice daily. If no effect is observed after 6 weeks, a trial of 400 Mg daily may be evaluated.
• Acute Pain & Dysmenorrhea: Initial loading dose of 400 Mg on Day 1 (followed by an additional 200 Mg if needed), then 200 Mg twice daily as needed.

Capsules may be taken with or without food. For patients who have difficulty swallowing, capsules can be carefully opened and the contents sprinkled over a level teaspoon of cool applesauce and ingested immediately with water.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Celecoxib vs Etoricoxib Comparison

Both celecoxib and etoricoxib belong to the COX-2 selective class, but they demonstrate distinct pharmacokinetic half-lives, receptor binding selectivities, and dosing regimens:

The choice between celecoxib and etoricoxib depends on jurisdictional regulatory availability, patient allergy history (notably sulfonamide hypersensitivity), cardiovascular risk stratification, and clinician guidance.

Who Should Not Take Celebrex 200 Mg?

Celebrex is contraindicated in patients with specific hypersensitivities, severe organ compromise, or elevated cardiovascular vulnerability:

• Known hypersensitivity to celecoxib or any component of the capsule
• History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• Known sulfonamide allergy: Celecoxib contains a sulfonamide moiety and can precipitate severe allergic reactions in sulfa-sensitive individuals
• In the setting of coronary artery bypass graft (CABG) surgery (immediate perioperative period)
• Active gastrointestinal ulceration, active GI bleeding, or inflammatory bowel disease
• Severe heart failure (NYHA Class II–IV) or uncontrolled hypertension
• Severe renal impairment (creatinine clearance < 30 mL/min) or severe hepatic impairment (Child-Pugh Class C)
• Third trimester of pregnancy (risk of premature closure of fetal ductus arteriosus and oligohydramnios)

Avoid use in patients with recent myocardial infarction unless benefits clearly outweigh the risk of recurrent cardiovascular events.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Possible Side Effects of Celebrex 200 Mg

Celebrex is generally well tolerated, but like all systemic NSAIDs, it can produce adverse reactions across multiple organ systems:

• Gastrointestinal: Dyspepsia, abdominal pain, diarrhea, flatulence, nausea, and vomiting.
• Cardiovascular / Renal: Fluid retention, peripheral edema, elevation of blood pressure, and renal function changes.
• Central Nervous System: Headache, dizziness, and insomnia.
• Dermatologic: Rash, pruritus, and rare severe cutaneous reactions (such as Stevens-Johnson syndrome or toxic epidermal necrolysis).

Patients must seek emergency care if they experience signs of cardiovascular compromise (chest pain, shortness of breath, slurred speech), gastrointestinal bleeding (black, tarry stools, coffee-ground emesis), or signs of liver injury (jaundice, right upper quadrant pain).
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Celebrex 200 Mg Drug Interactions

Inform your physician and pharmacist of all prescription and over-the-counter medications you are currently using:

Anticoagulants & Antiplatelets: Concomitant use with warfarin, heparin, direct oral anticoagulants (DOACs), or low-dose aspirin significantly escalates the risk of severe upper gastrointestinal bleeding. Prothrombin time/INR must be monitored closely when initiating or adjusting celecoxib in patients on warfarin.

Antihypertensives (ACE Inhibitors, ARBs, Beta-blockers, Diuretics): NSAIDs may diminish the antihypertensive effect of ACE inhibitors, angiotensin receptor blockers, and thiazide or loop diuretics, while increasing the risk of acute renal deterioration.

Lithium & Methotrexate: Celecoxib can reduce the renal clearance of lithium and methotrexate, leading to increased plasma concentrations and potential clinical toxicity.

CYP2C9 Inhibitors & Substrates: Celecoxib is primarily metabolized by CYP2C9. Co-administration with fluconazole doubles celecoxib plasma concentrations, requiring a 50% dose reduction. Celecoxib is also an inhibitor of CYP2D6 and may increase exposure to CYP2D6 substrates (such as dextromethorphan, metoprolol, or tricyclic antidepressants).
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Hepatic, Renal, and Cardiovascular Considerations

Long-term use of NSAIDs inhibits renal prostaglandin synthesis, which can decrease renal blood flow and precipitate overt renal decompensation in patients with pre-existing kidney dysfunction, dehydration, or heart failure. Renal function (eGFR/creatinine) and serum electrolytes should be checked periodically.

In patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose of Celebrex should be reduced by 50%. Celebrex is not recommended for patients with severe hepatic impairment.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Treatment Duration and GI Safety Profile

While celecoxib demonstrates significantly lower rates of endoscopically confirmed gastroduodenal ulcers compared to traditional non-selective NSAIDs, it does not eliminate gastrointestinal risk entirely.

Patients at high risk for GI complications (such as elderly individuals, those with a prior history of peptic ulcer disease, or those taking systemic corticosteroids or anticoagulants) should be evaluated for co-prescription of gastroprotective agents, such as proton pump inhibitors (PPIs), even when using a selective COX-2 inhibitor.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29bfa881-bfd8-4f81-baee-6be0eb24d770))

Official Medical Reference

For comprehensive clinical trial data, official FDA black-box warnings, contraindications, drug metabolism profiles, and approved dosing indications, consult the official DailyMed prescribing monograph:

DailyMed – Celebrex (Celecoxib Capsules) Prescribing Information

Frequently Asked Questions About Celebrex 200 Mg

Medical Disclaimer

This product summary is prepared strictly for educational and informational purposes. Celebrex (celecoxib) is a prescription-only nonsteroidal anti-inflammatory medication that must be initiated, dosed, and monitored under the supervision of a licensed physician. Individual prescribing decisions must take into account cardiovascular risk profiles, gastrointestinal history, renal and hepatic parameters, and concurrent pharmacological regimens. This information does not replace clinical medical evaluation, diagnosis, or personalized therapeutic care.